-
1
-
-
47049093923
-
-
Statistics of Cancer, National Cancer Center, Japan
-
Statistics of Cancer. Center for Information Services. National Cancer Center, Japan, http://ganjoho.ncc.go.jp/public/statistics/pub/ update.html.
-
Center for Information Services
-
-
-
2
-
-
0027217474
-
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer
-
Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993:72:37-41.
-
(1993)
Cancer
, vol.72
, pp. 37-41
-
-
Murad, A.M.1
Santiago, F.F.2
Petroianu, A.3
Rocha, P.R.4
Rodrigues, M.A.5
Rausch, M.6
-
3
-
-
0028006253
-
Initial or delayed chemotherapy with best supportive care in advanced gastric cancer
-
Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994:5:189-90.
-
(1994)
Ann Oncol
, vol.5
, pp. 189-190
-
-
Glimelius, B.1
Hoffman, K.2
Haglund, U.3
Nyren, O.4
Sjoden, P.O.5
-
4
-
-
0028959887
-
Randomized comparison of fluorouracill, epidoxorubicin and methotrexate (FEMTX) plus best supportive care alone in patients with non-resectable gastric cancer
-
Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracill, epidoxorubicin and methotrexate (FEMTX) plus best supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
-
(1995)
Br J Cancer
, vol.71
, pp. 587-591
-
-
Pyrhonen, S.1
Kuitunen, T.2
Nyandoto, P.3
Kouri, M.4
-
5
-
-
0003859172
-
5-Fluorouracil-methotrexate synergy: Enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthase by dihydropteroylpolyglutamates
-
Fernandes DJ, Bertino JR. 5-Fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. Proc Natl Acad Sci USA 1980;77:5663-7.
-
(1980)
Proc Natl Acad Sci USA
, vol.77
, pp. 5663-5667
-
-
Fernandes, D.J.1
Bertino, J.R.2
-
6
-
-
0018700143
-
Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism
-
Cadman E, Heimer R, Davis L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. Science 1979;205:1135-7.
-
(1979)
Science
, vol.205
, pp. 1135-1137
-
-
Cadman, E.1
Heimer, R.2
Davis, L.3
-
7
-
-
0024414365
-
Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial
-
Nordic Gastrointestinal Tumor Adjuvant Therapy Group
-
Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. J Clin Oncol 1989;7:1437-46.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1437-1446
-
-
-
8
-
-
0028219974
-
Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer
-
Advanced Colorectal Cancer Meta-Analysis Project
-
Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12:960-9
-
(1994)
J Clin Oncol
, vol.12
, pp. 960-969
-
-
-
9
-
-
0345337429
-
Biochemical modulation of 5-fluoroumcil by methotrexate in patients with advancel gastric carcinoma
-
Perez JE, Lacava JA, Dominguez ME, Rodriguez R, Barbieri MR, Ortiz EH et al. Biochemical modulation of 5-fluoroumcil by methotrexate in patients with advancel gastric carcinoma. Am J Clin Oncol 1998;21:452-7.
-
(1998)
Am J Clin Oncol
, vol.21
, pp. 452-457
-
-
Perez, J.E.1
Lacava, J.A.2
Dominguez, M.E.3
Rodriguez, R.4
Barbieri, M.R.5
Ortiz, E.H.6
-
10
-
-
0024345783
-
Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma
-
Dickinson R, Preagrave P, Levi J, Milliken S. Woods R. Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma. Cancer Chemother Pharmacol 1989;24:67-8.
-
(1989)
Cancer Chemother Pharmacol
, vol.24
, pp. 67-68
-
-
Dickinson, R.1
Preagrave, P.2
Levi, J.3
Milliken, S.4
Woods, R.5
-
11
-
-
0024433274
-
Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer
-
Sasaki T, Ota K, Ibayashi J, Sakata Y, Matsuoka T, Ishikawa M et al. Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer. Jpn J Cancer Chemother 1989; 16:2545-55.
-
(1989)
Jpn J Cancer Chemother
, vol.16
, pp. 2545-2555
-
-
Sasaki, T.1
Ota, K.2
Ibayashi, J.3
Sakata, Y.4
Matsuoka, T.5
Ishikawa, M.6
-
12
-
-
0003252333
-
Response assessment of chemotherapy for gastric carcinoma
-
Japanese Research Society for Gastric Cancer, 1st edn Tokyo, Kanchara
-
Japanese Research Society for Gastric Cancer. Response assessment of chemotherapy for gastric carcinoma. Japanese Classification of Gastric Carcinoma. 1st edn Tokyo, Kanchara, 1995,90-104.
-
(1995)
Japanese Classification of Gastric Carcinoma
, pp. 90-104
-
-
-
13
-
-
17444454475
-
Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group
-
Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993;23:250-7.
-
(1993)
Jpn J Clin Oncol
, vol.23
, pp. 250-257
-
-
Tobinai, K.1
Kohno, A.2
Shimada, Y.3
Watanabe, T.4
Tamura, T.5
Takeyama, K.6
-
14
-
-
0019969601
-
Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer
-
Cocconi G, DeLisi V, Di Blasio B. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treatment Rep 1982; 56:1263-6.
-
(1982)
Cancer Treatment Rep
, vol.56
, pp. 1263-1266
-
-
Cocconi, G.1
DeLisi, V.2
Di Blasio, B.3
-
15
-
-
84944367593
-
A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin
-
Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-7.
-
(1985)
JAMA
, vol.253
, pp. 2061-2067
-
-
Cullinan, S.A.1
Moertel, C.G.2
Fleming, T.R.3
Rubin, J.R.4
Krook, J.E.5
Everson, L.K.6
-
16
-
-
0027198871
-
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer
-
Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-8.
-
(1993)
Cancer
, vol.71
, pp. 3813-3818
-
-
Kim, N.K.1
Park, Y.S.2
Heo, D.S.3
Suh, C.4
Kim, S.Y.5
Park, K.C.6
-
17
-
-
18744373000
-
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)
-
Ohta J A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-9.
-
(2003)
J Clin Oncol
, vol.21
, pp. 54-59
-
-
Ohta, J.A.1
Shimada, Y.2
Shirao, K.3
Boku, N.4
Hyodo, I.5
Saito, H.6
-
18
-
-
0031015454
-
Fluorouracil in colorectal cancer-a tale of two drugs: Implications for biochemical modulation
-
Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer-a tale of two drugs: Implications for biochemical modulation. J Clin Oncol 1997;15:368-81.
-
(1997)
J Clin Oncol
, vol.15
, pp. 368-381
-
-
Sobrero, A.F.1
Aschele, C.2
Bertino, J.R.3
-
19
-
-
0034830598
-
Phase II trial of paclitaxel by threc-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions
-
Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H et al. Phase II trial of paclitaxel by threc-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001;12:1133-7.
-
(2001)
Ann Oncol
, vol.12
, pp. 1133-1137
-
-
Yamada, Y.1
Shirao, K.2
Ohtsu, A.3
Boku, N.4
Hyodo, I.5
Saitoh, H.6
-
20
-
-
0028276113
-
Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group
-
Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Jpn J Cancer Chemother 1994;21:1033-8.
-
(1994)
Jpn J Cancer Chemother
, vol.21
, pp. 1033-1038
-
-
Futatsuki, K.1
Wakui, A.2
Nakao, I.3
Sakata, Y.4
Kambe, M.5
Shimada, Y.6
-
21
-
-
6044256382
-
Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: A report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial
-
Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: A report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol. 2004;34:316-22.
-
(2004)
Jpn J Clin Oncol
, vol.34
, pp. 316-322
-
-
Yamao, T.1
Shimada, Y.2
Shirao, K.3
Ohtsu, A.4
Ikeda, N.5
Hyodo, I.6
|